Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04772391
Other study ID # IRB-300006888
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date October 1, 2022

Study information

Verified date December 2022
Source Memorial Healthcare System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this project is to develop novel approaches to promote health and longevity while enhancing quality of life among persons with Sickle cell disease (SCD). Therefore, investigators are aiming to adapt an evidence-based exercise intervention for adults with SCD informed by culturally- relevant and biologic factors and pre-test the adapted exercise program in a small sample of adults with SCD.


Description:

Sickle cell disease (SCD) is a major public health concern as it is the most common inherited blood disorder in the US, affecting over 100,000 persons.(1) This disease predominantly affects African Americans, occurring in 1 out 365 African American births. Sickle cell disease causes intermittent extremely painful vaso-occlusion events, which lead to multi-organ damage, significant morbidity and early mortality - and resulting in increased healthcare utilization with estimated annual United States healthcare costs of 786 million.(2,3) To date, there are very few strategies for reducing pain, preventing organ dysfunction, and improving quality of life for persons with SCD leading to a disproportionate disparity in care. For this reason, there is a critical need to develop novel approaches to promote health and longevity while enhancing quality of life among persons with SCD. Exercise capacity and cardiorespiratory fitness are important predictors of cardiovascular outcomes and overall survival; however, adults with SCD have severely reduced levels of fitness, with less than 50% of expected compared to the general population. (4) Since cardiopulmonary disease accounts for 40% of the mortality in adults with SCD, enhancing physical activity with regular exercise is one potential method for improving survival, reducing poor Cardiovascular disease (CVD) outcomes, and improving quality of life for adults with SCD.(5,6) Evidence-based exercise interventions in rheumatoid arthritis, an inflammatory, chronic disease with similar sequelae to SCD, have shown that exercise interventions can increase quality of life, reduce pain, and improve CVD outcomes.(7-9) Currently, a paucity of research on the benefits of exercise for SCD exists and this is a critical barrier to overcome to both understand the role of physical fitness SCD and to develop evidence-based recommendations to guide exercise in SCD. Only one small study of an exercise intervention program in France has reported exercise to be safe, effective, and reverse SCD-related muscle vasculature damage but long term data in larger populations are needed.(10) Therefore, there is a need to conduct more studies in the United States and to develop an evidence-based exercise program for adults with SCD that integrates patient perspectives, can be broadly implemented among different settings, and is physically safe. To address this unmet need, the central hypothesis of this proposal is that an evidence-based exercise intervention informed by the needs and preferences of adults with SCD will be feasible, acceptable, and tolerable in a cohort of adults with SCD. Our long-term goal is to develop a safe and effective exercise intervention to promote sustainable physical activity in SCD and to guide exercise recommendations for SCD which currently do not exist. Therefore, investigators propose to adapt an evidence-based exercise intervention for adults with SCD informed by culturally- relevant and biologic factors and pre-test the adapted exercise program in a small sample of adults with SCD. Outcomes: The primary outcome will be to collect preliminary data on feasibility, acceptability, and tolerability of the exercise intervention. Rates of recruitment and retention will be measured to assess feasibility. Acceptability will be measured through attendance, engagement, and qualitative feedback. Tolerability will be measured by the ability for participants to complete the exercise program without adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant must have sickle cell disease of any genotype - Participant must be 18 years of age - Participant must be seen and followed by the UAB sickle cell center - Participant must have reliable transportation to the UAB center of Exercise Medicine - Participant must be in steady-state disease (No vaso-occlusive crisis or SCD-related hospitalization with 4 weeks of enrollment) Exclusion Criteria: - Participant has avascular necrosis - Participant is pregnant - Participant has absolute contraindications to exercise according to the American Heart Association and American College of Sports Medicine guidelines (42)

Study Design


Intervention

Other:
Exercise Sessions
Participant will complete up to 8 exercise sessions

Locations

Country Name City State
United States Memorial Healthcare System Hollywood Florida

Sponsors (1)

Lead Sponsor Collaborator
Memorial Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility will be measured Outcome will be to collect preliminary data on feasibility of the exercise intervention using rates of recruitment and retention One year
Primary Acceptability will be measured Outcome will be to collect preliminary data on acceptability of the exercise intervention using attendance, engagement, and qualitative feedback. One year
Primary Tolerability will be measured Outcome will be to collect preliminary data on tolerability of the exercise intervention using the ability for participants to complete the exercise program without adverse events. One year
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)